

EMA/23043/2016

## European Medicines Agency decision

P/0028/2016

of 29 January 2016

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 17 beta-estradiol / etonogestrel (EMA-001718-PIP01-14) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

### **Disclaimer**

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

**Only the English text is authentic.**

# European Medicines Agency decision

P/0028/2016

of 29 January 2016

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 17 beta-estradiol / etonogestrel (EMA-001718-PIP01-14) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004<sup>1</sup>,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency<sup>2</sup>,

Having regard to the application submitted by Merck Sharp & Dohme (Europe), Inc. on 10 December 2014 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 11 December 2015, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

---

<sup>1</sup> OJ L 378, 27.12.2006, p.1.

<sup>2</sup> OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

**Article 1**

A paediatric investigation plan for 17 beta-estradiol / etonogestrel, vaginal delivery system, vaginal use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

**Article 2**

A deferral for 17 beta-estradiol / etonogestrel, vaginal delivery system, vaginal use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 3**

A waiver for 17 beta-estradiol / etonogestrel, vaginal delivery system, vaginal use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 4**

This decision is addressed to Merck Sharp & Dohme (Europe), Inc., Clos du Lynx, 5, 1200 - Brussels, Belgium.

Done at London, 29 January 2016

For the European Medicines Agency  
Zaïde Frias  
Head of Division  
Human Medicines Research and Development Support  
(Signature on file)



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/PDCO/105268/2015  
London, 11 December 2015

## Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-001718-PIP01-14

### Scope of the application

**Active substance(s):**

17 beta-estradiol / etonogestrel

**Condition(s):**

Prevention of pregnancy

Treatment of dysmenorrhea

**Pharmaceutical form(s):**

Vaginal delivery system

**Route(s) of administration:**

Vaginal use

**Name/corporate name of the PIP applicant:**

Merck Sharp & Dohme (Europe), Inc.

### Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Merck Sharp & Dohme (Europe), Inc. submitted for agreement to the European Medicines Agency on 10 December 2014 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 20 January 2015.

Supplementary information was provided by the applicant on 11 September 2015. The applicant proposed modifications to the paediatric investigation plan.



## Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

## **Annex I**

**The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)**

# 1. Waiver

## 1.1. Conditions

Prevention of pregnancy

Treatment of dysmenorrhea

The waiver applies to:

- boys from birth to less than 18 years of age, and girls from birth to age at menarche;
- for vaginal delivery system, vaginal use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subsets.

# 2. Paediatric investigation plan

## 2.1. Conditions

Prevention of pregnancy

Treatment of dysmenorrhea

### 2.1.1. Indication(s) targeted by the PIP

1. Contraception;
2. Treatment of primary dysmenorrhea, in adolescents seeking contraception.

### 2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From age at menarche to less than 18 years of age

### 2.1.3. Pharmaceutical form(s)

Vaginal delivery system, vaginal use

### 2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	0	Not applicable.
Clinical studies	1	Open label, pharmacokinetic and pharmacodynamic study in healthy post-menarcheal adolescents in comparison to healthy young adult females (P072).

Extrapolation, modelling and simulation studies	0	Not applicable.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

### 3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2017
Deferral for one or more measures contained in the paediatric investigation plan:	Yes